Insilico Med, 4B Tech partner on neurodegenerative drug discovery

By The Science Advisory Board staff writers

August 27, 2021 -- Insilico Medicine is collaborating with 4B Technologies to develop small-molecule therapies for amyotrophic lateral sclerosis (ALS) and other major neurological diseases.

The companies said the collaboration will leverage Insilico's synthetic biology and synthetic chemistry artificial intelligence platform and 4B Technologies' insights in targeting strategies, biology, translational research, and clinical medicine in the field of neurological diseases.

Insilico uses artificial intelligence to develop kidney fibrosis drug candidate
Insilico Medicine has developed a preclinical candidate for kidney fibrosis that has the desired pharmacological properties and pharmacokinetic profile,...

Copyright © 2021

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter